Articles > Zenas BioPharma, Inc. (ZBIO) Shareholders Alert
- Several law firms are urging Zenas BioPharma, Inc. investors to contact them before June 16, 2025, regarding potential recovery under federal securities laws.
- Shareholders who suffered losses on their ZBIO investment have the opportunity to lead class action lawsuits against the company.
- Investors who purchased Zenas BioPharma securities may be entitled to compensation without out-of-pocket fees.
- Pomerantz Law Firm, Levi & Korsinsky, and other top-ranked investor counsel are actively involved in representing ZBIO investors.
- The deadline for Zenas BioPharma investors with substantial losses to seek appointment as lead plaintiff in class action lawsuits is June 16, 2025.
Zenas BioPharma, Inc. (ZBIO) shareholders are being urged to protect their rights by various law firms before June 16, 2025. Levi & Korsinsky, a notable legal entity, is offering assistance to investors who have suffered losses on their ZBIO investments and wish to explore potential recovery under federal securities laws. If you are in this position, you are advised to contact Levi & Korsinsky or visit their website for more information.
Additionally, Rosen Law Firm, a global investor rights law entity, is reminding Zenas BioPharma, Inc. investors about the upcoming June 16, 2025 lead plaintiff deadline in the securities class action initially filed by the firm. Shareholders who purchased Zenas BioPharma securities may be eligible for compensation without having to pay any out-of-pocket fees through a contingency fee arrangement.
Moreover, Pomerantz Law Firm has announced a class action lawsuit against Zenas BioPharma, Inc. ("Zenas" or the "Company") for investors who have suffered losses on their ZBIO investment. Investors are encouraged to reach out to Danielle Peyton at Pomerantz Law Firm for assistance in this matter.
Furthermore, Robbins Geller Rudman & Dowd LLP has notified investors with substantial losses that they have until June 16, 2025, to seek appointment as lead plaintiff of the Zenas BioPharma class action lawsuit. The firm is offering representation to purchasers or acquirers of ZBIO securities traceable to the company's initial public offering in September 2024.
Bronstein, Gewirtz & Grossman, LLC has also filed a class action lawsuit against Zenas BioPharma, Inc. ("Zenas BioPharma" or "the Company") and certain officers for alleged violations of federal securities laws. The lawsuit aims to recover damages for all individuals and entities that purchased ZBIO securities in connection with the company's IPO in September 2024.
Zenas BioPharma, Inc. investors facing losses on their investments have the opportunity to take legal action against the company. Various law firms are available to assist shareholders in exploring potential recovery under federal securities laws before the June 16, 2025 deadline.
For more information:
Up/Down Rally Price Distribution Analyst Recommendations Earning Price Impact Analysis Seasonality
Zenas BioPharma, Inc. (ZBIO) Shareholders Alert
By KlickAnalytics Data Insights | May 27, 2025 08:00PM ET
Key Points
- Several law firms are urging Zenas BioPharma, Inc. investors to contact them before June 16, 2025, regarding potential recovery under federal securities laws.
- Shareholders who suffered losses on their ZBIO investment have the opportunity to lead class action lawsuits against the company.
- Investors who purchased Zenas BioPharma securities may be entitled to compensation without out-of-pocket fees.
- Pomerantz Law Firm, Levi & Korsinsky, and other top-ranked investor counsel are actively involved in representing ZBIO investors.
- The deadline for Zenas BioPharma investors with substantial losses to seek appointment as lead plaintiff in class action lawsuits is June 16, 2025.
Zenas BioPharma, Inc. (ZBIO) shareholders are being urged to protect their rights by various law firms before June 16, 2025. Levi & Korsinsky, a notable legal entity, is offering assistance to investors who have suffered losses on their ZBIO investments and wish to explore potential recovery under federal securities laws. If you are in this position, you are advised to contact Levi & Korsinsky or visit their website for more information.
Additionally, Rosen Law Firm, a global investor rights law entity, is reminding Zenas BioPharma, Inc. investors about the upcoming June 16, 2025 lead plaintiff deadline in the securities class action initially filed by the firm. Shareholders who purchased Zenas BioPharma securities may be eligible for compensation without having to pay any out-of-pocket fees through a contingency fee arrangement.
Moreover, Pomerantz Law Firm has announced a class action lawsuit against Zenas BioPharma, Inc. ("Zenas" or the "Company") for investors who have suffered losses on their ZBIO investment. Investors are encouraged to reach out to Danielle Peyton at Pomerantz Law Firm for assistance in this matter.
Furthermore, Robbins Geller Rudman & Dowd LLP has notified investors with substantial losses that they have until June 16, 2025, to seek appointment as lead plaintiff of the Zenas BioPharma class action lawsuit. The firm is offering representation to purchasers or acquirers of ZBIO securities traceable to the company's initial public offering in September 2024.
Bronstein, Gewirtz & Grossman, LLC has also filed a class action lawsuit against Zenas BioPharma, Inc. ("Zenas BioPharma" or "the Company") and certain officers for alleged violations of federal securities laws. The lawsuit aims to recover damages for all individuals and entities that purchased ZBIO securities in connection with the company's IPO in September 2024.
Zenas BioPharma, Inc. investors facing losses on their investments have the opportunity to take legal action against the company. Various law firms are available to assist shareholders in exploring potential recovery under federal securities laws before the June 16, 2025 deadline.
For more information:
Disclaimer: the above is a summary showing certain market information. KlickAnalytics is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from various resources and more. Communications displaying market prices, data and other information available in this post are meant for purely for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.